Moderated Poster Discussions - T2 Research/Science
Tuesday, April 14, 2026
4:45 pm - 6:15 pm
T2 Research/Science: Translation to patients, including Phase 2 and 3 clinical trials, and controlled studies leading to clinical application and evidence-based guidelines.
FLUOROQUINOLONE USE AND INCIDENCE OF RETINAL DETACHMENT (Diagnosis or Treatment of a Disease Process or Clinical Syndromes)
Benjamin Jones, BS, University of Toledo College of Medicine and Life Sciences
Fluoroquinolones have been theorized to increase the risk of retinal detachment.
EFFICACY AND SAFETY OF ORAL METOCLOPRAMIDE COMPARED WITH NASAL METOCLOPRAMIDE IN DIABETIC GASTROPARESIS: SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS (Gastroenterology / Clinical Nutrition)
Hamzeh Abugharbieh, University of Toledo
Diabetic gastroparesis is a chronic complication of diabetes characterized by delayed gastric emptying in the absence of mechanical obstruction due to diabetes-related neuronal dysfunction. Symptoms include nausea, retching, vomiting, early satiety, postprandial fullness, abdominal pain, bloating, and abdominal distension. Management strategies focus on glycemic control, dietary modifications, and pharmacologic therapy, with procedural and surgical interventions reserved for refractory disease. Pharmacologic treatment with metoclopramide remains the first-line therapy. Oral metoclopramide has been approved since 1980, while a nasal formulation received approval in 2020, and both have demonstrated symptomatic improvement in clinical trials. However, direct comparative evidence regarding the efficacy and safety of these formulations is limited.
AN INTEGRATED ANALYSIS OF CHEMICAL SIMILARITY, TRANSCRIPTOMIC PROFILING, AND REAL-WORLD NEUROPSYCHIATRIC OUTCOMES FOR LEVETIRACETAM (Neurology)
Andrew Edgington, BS, University of Toledo College of Medicine & Life Sciences
Levetiracetam (LEV) is widely prescribed for epilepsy and is frequently discussed in relation to behavioral and psychiatric adverse effects. However, long-term comparative neuropsychiatric outcomes across antiepileptic drugs (AEDs) remain incompletely characterized, and the descriptive value of molecular profiling remains unclear. We integrated chemical similarity analysis, transcriptomic perturbation data, and real-world clinical outcomes to compare LEV with commonly prescribed AEDs.
ONE IN FOUR IPF CLINICAL TRIALS END EARLY REASONS FOR DISCONTINUATION AND STRATEGIES TO IMPROVE TRIAL SUCCESS (Pulmonary / Critical Care)
Thaer Alhroob, MD, The University of Toledo Medical Center
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal interstitial lung disease for which clinical trials are essential to develop effective therapies. Early discontinuation of trials wastes resources, exposes participants to risk without benefit, and delays therapeutic progress, yet the frequency and reasons for IPF trial termination across phases, sponsors, and regions are not well defined.